Article

Catalent's SMARTag ADC Stands Out In The Crowd Of HER2-Targeted Conjugates

Source: Catalent

By Penelope Drake, Ph.D., Head of R&D, Bioconjugates, Catalent Biologics

research-microscope-samples-iStock-1220382399

The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, Kadcyla® (adotrastuzumab emtansine/T-DM1(1)), which comprises the trastuzumab antibody appended through a noncleavable linker to the potent microtubule inhibitor payload, maytansine. T-DM1 was the first approved ADC against a solid tumor indication(2), and its efficacy showed the promise of HER2-targeted therapies; follow-on molecules have been designed with the goal of improving upon this first-generation drug and thereby continue to raise the bar for patient outcomes. However, the sheer number of follow-on candidates makes it difficult to keep track of the state-of-the-art, and for those not immersed in the field, it can be hard to differentiate among the many iterations in order to find the true innovations in the crowd.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: